XenTech to be Represented at Bio International Convention 2013

Press Release – XenTech
XenTech to be Represented at Bio International Convention 2013

XenTech Logo

Contact Supplier: XenTech
Supplier Press Release: XenTech to be Represented at Bio International Convention 2013
Address: 4, rue Pierre Fontaine, F 91000 Evry, France
Tel: +33 1 60 87 89 80
Fax: +33 1 60 87 89 62
Website: www.xentech.eu

APRIL 15, 2013

XenTech to be Represented at Bio International Convention 2013

XenTech, biotech and CRO specialist in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets will be attending the Bio International Convention 2013.

The annual Bio International Convention, will take place on 22nd -25th April at the McCormick Place, Chicago USA.

Throughout the event, XenTech’s representative, Pascal Leuraud will be available to meet with attendees to discuss XenTech’s services and what the company can offer.

This will be the XenTech’s third time of attending the conference, following previous successful appearances. Pascal Leuraud commented regarding the event: ‘Bio International Convention has become an integral part of our event calendar, due to, in part, the number of relevant attendees and the opportunity it gives us to create new business relationships.’ He continued: ‘We are very much looking forward to this year’s event and hope that it is as successful as previous years.’

XenTech are inviting interested attendees to contact them to make an appointment to meet with Pascal during the event. Please email Pascal on contact-bio@xentech.eu

About XenTech
XenTech is an innovative biotech/CRO company specialising in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

Its PDX models are extensively characterized and are associated to molecular data including gene expression and copy number data. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.

XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.

About Bio International Convention 2013
Bio International Convention is the global event for the biotechnology industry attracting over 16,000 decision makers from 65 countries. The three day event attracts thousands of companies from around the world and helps build strategic partnerships. BIO covers the wide spectrum of life science innovations and application areas. Drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy are just a few of the industries represented at the BIO International Convention.

For more information or to discuss XenTech attending Bio International Convention 2013 please contact XenTech directly.

Comments are closed.